Pharsight Announces New DMX(TM) Web Server Release to Support Oracle and SAS XPORT
Pharsight Corporation , a leading provider of software and strategic services designed to optimize clinical drug development, today announced the release of Drug Model Explorer(TM) Web Server (DMX(TM)) 1.4. The new release will support Oracle(R) and allow DMX to read and process simulation data created in SAS(R) XPORT transport format. Oracle is the preferred database system in the pharmaceutical industry and SAS XPORT is a data exchange mechanism accepted by the Food and Drug Administration (FDA).
DMX is a web-based tool that allows clinical drug development teams to communicate, present and exchange information on drug attributes quickly and efficiently and compare probable outcomes based on different treatment strategies, patient populations and competing products.
DMX will continue to support Microsoft(R) SQL Server, a leading database product, and will continue to process simulations created in S-PLUS(R), a leading analysis software product.
“We are committed to working closely with our customers to meet their changing and emerging technology needs,” said Shawn M. O‘Connor, President and Chief Executive Officer. “By supporting Oracle and SAS XPORT format in DMX, the value of our software products increases through enhanced compatibility with our customers’ existing workflows and drug development technology infrastructures. Our customers highly value products that will allow them to focus more resources on their core business of drug development, and not, for example, on information technology. By incorporating this upgraded functionality that is directly in response to our customers’ needs so quickly after our commercial launch, we believe we are illustrating our commitment to being responsive to our customers and to remaining at the forefront of technology development.”
About DMX
DMX allows clinicians, biostatisticians, marketers, and other members of clinical development teams to quickly visualize the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process. DMX can enhance the entire development team’s understanding of a drug’s likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables.
Key new features and functionality of DMX Web Server 1.4 include: — Support for Oracle, the preferred database system in the pharmaceutical industry — Ability to read and process simulations created in SAS XPORT format, a data exchange mechanism accepted by the FDA — Desktop publishing tools no longer require installation of source software (S-PLUS, SAS) used to generate DMX-ready simulations, increasing ease of deployment — Publishing tools support packaging of all simulation objects into a single file About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers’ development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at www.pharsight.com .
NOTE: Pharsight, WinNonlin and WinNonMix, Pharsight Knowledgebase Server, PKS, Drug Model Explorer, DMX, PKS Reporter and Trial Simulator are registered trademarks or trademarks of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks of their respective holders.
Web site: http://www.pharsight.com/
